TRDA
Entrada Therapeutics
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: TRDA
- PE Ratio
The current PE ratio of TRDA can't be determined, as the TTM EPS of -$3.99 is negative. Entrada Therapeutics's last PE ratio on record was 11.16 in March 2025.
TRDA PE ratio history
The mean historical PE ratio of Entrada Therapeutics over the last four years is 8.44. In the past four years, TRDA's PE ratio reached its highest point in the Mar 2024 quarter at 20.24, with a price of $14.17 and an EPS of $0.7. The Sep 2022 quarter saw the lowest point at 1.14, with a price of $15.76 and an EPS of $13.79.
Entrada Therapeutics PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | N/A | N/A | $10.28 | -$3.47 |
| 2024 | 9.82 | N/A | $17.29 | $1.76 |
| 2023 | N/A | N/A | $15.09 | -$0.2 |
| 2022 | N/A | N/A | $13.52 | -$3.02 |
| 2021 | N/A | N/A | $17.12 | -$8.16 |
| 2020 | N/A | N/A | N/A | -$24 |
| 2019 | N/A | N/A | N/A | -$0.76 |
Entrada Therapeutics PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | N/A | N/A | $12.62 | -$3.99 |
| Dec 2025 | N/A | N/A | $10.28 | -$3.47 |
| Sep 2025 | N/A | N/A | $5.8 | -$2.55 |
| Jun 2025 | N/A | N/A | $6.72 | -$1.84 |
| Mar 2025 | 11.16 | 13.65% | $9.04 | $0.81 |
| Dec 2024 | 9.82 | 2.61% | $17.29 | $1.76 |
| Sep 2024 | 9.57 | 107.59% | $15.98 | $1.67 |
| Jun 2024 | 4.61 | -77.22% | $14.25 | $3.09 |
| Mar 2024 | 20.24 | N/A | $14.17 | $0.7 |
| Dec 2023 | N/A | N/A | $15.09 | -$0.2 |
| Sep 2023 | N/A | N/A | $15.8 | -$0.7 |
| Jun 2023 | N/A | N/A | $15.14 | -$2.57 |
| Mar 2023 | N/A | N/A | $14.5 | -$2.53 |
| Dec 2022 | N/A | N/A | $13.52 | -$3.02 |
| Sep 2022 | 1.14 | -54.94% | $15.76 | $13.79 |
TRDA Price vs fair value
TRDA average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
PE comparison
TRDA PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| REGN Regeneron Pharmaceuticals Inc | 14.76 | $65.86B |
| GILD Gilead Sciences Inc | 17.41 | $160.42B |
| BIIB Biogen Inc | 21.02 | $29.02B |
| AMGN Amgen Inc | 23.87 | $186.56B |
| VRTX Vertex Pharmaceuticals Inc | 25.97 | $112.13B |
| NTLA Intellia Therapeutics Inc | N/A | $2.07B |
| MRNA Moderna Inc | N/A | $20.34B |
| CRSP CRISPR Therapeutics AG | N/A | $5.49B |
| EDIT Editas Medicine Inc | N/A | $292.74M |
| TRDA Entrada Therapeutics Inc | N/A | $271.55M |
Frequently asked questions
What is Entrada Therapeutics's PE ratio?
The current price to earnings ratio of TRDA can't be calculated, as its EPS of -$3.99 is negative.
What is the 3-year average PE ratio for Entrada Therapeutics (TRDA)?
As an average over the last 3 years, TRDA stock has a PE ratio of 11.08.
What is the highest PE ratio for TRDA?
In the last four years, the Mar 2024 quarter recorded the highest quarterly PE ratio at 20.24.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.